Overview | November 24, 2025
FFPE Multi-Omics for Translational Oncology
Get the Resource
Download NowTranslational oncology teams must show that a therapeutic engages its target and modulates downstream pathways in patient tissue. Yet:
- Archival trial biopsies yield limited molecular data.
- Fresh tissue sampling is impractical for most studies.
- Mechanistic and pharmacodynamic (PD) signals are split across platforms.
The result? Uncertainty around proof-of-mechanism and delayed go/no-go decision-making.
Enable quantitative, translational proteogenomics in archival tissue with Sapient's FFPE Proteomics services.
From a 5 µm FFPE section, Sapient’s FFPE Proteomics workflows quantify >10,000 protein groups, including phospho- and glyco-proteins, splice isoforms, and cleavage variants – revealing insights into tumor signaling, immune activation, target engagement, pathway modulation, and pharmacodynamic effects with single protein and pathway-level resolution.
Now, through the quantitative measure of target pathway activation and modulation in FFPE tissue, translational oncology teams can rapidly test mechanistic hypotheses and correlate pathway activation with clinical response – enabling rapid proof-of-mechanism and earlier dose and target engagement decisions.
Download the data sheet to learn more about our FFPE Proteomics services and how they are designed to accelerate translational oncology – including with streamlined access to thousands of annotated FFPE samples via Sapient’s DynamIQ™ virtual biobank, enabling rapid cross-validation of target engagement and pathway modulation in existing FFPE tissue before committing to costly Phase 2 trials.
You’ll also see how Sapient’s FFPE Multi-Omics platform additionally integrates DNA sequencing, single-cell sequencing, and spatial profiling to enable comprehensive molecular mapping of the tumor, immune, and stromal compartments in one dataset.